← Eichor
Study identifier: NCT07264634 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Condition: Hypoparathyroidism  ·  Sponsor: Ascendis Pharma A/S

PhaseN/A
Planned participants10
Who can joinFemale, 18 Years to 50 Years
Healthy volunteersNo

About this study

This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.

This description comes directly from the study's public registry record.

Talk to the study team

Yorvipath Lactation Inquiries  ·  877-229-2184  ·  yorvipathlactation@ubc.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ascendis Investigational SiteMorgantown, West Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07264634